en · de · es · fr · pt
sr9009-notes.peptides4800.com › Data › Background And Research Status — What the Evidence Shows

Background And Research Status — What the Evidence Shows

By Editorial Desk · published 2025-09-03 · last reviewed 2025-10-07 · Data

SR9009 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2025-10-07. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Research Status

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

Mechanism and Preclinical Findings

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Sr9009 at a glance

PropertyValueNotes
Common nameSR9009Also referred to as Stenabolic in non-scientific contexts.
Chemical classSynthetic small moleculeNot a steroid or peptide hormone.
Receptor targetREV-ERBα and REV-ERBβNuclear receptor agonist in preclinical studies.
Development statusInvestigationalNo approved human therapeutic indication.
Regulatory attentionProhibited in sportListed by anti-doping authorities.

Detection, Regulation, and Misconceptions

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Related pages on this site

Reference notes

== Structure == Several structures of glyoxalase I have been solved. Four structures of the human form have been published, with PDB accession codes PDB: 1BH5​, PDB: 1FRO​, PDB: 1QIN​, and PDB: 1QIP​. Five structures of the Escherichia coli form have been published, with accession codes PDB: 1FA5​, PDB: 1FA6​, PDB: 1FA7​, PDB: 1FA8​, and PDB: 1F9Z​. Finally, one structure of the trypanothione-specific version from Leishmania major has been solved, PDB: 2C21​. In all these cases, the quaternary structure of the biological unit is a domain-swapped dimer, in which the active site and the 8-stranded beta sheet secondary structure is formed from both subunits. However, in yeast such as Saccharomyces cerevisiae, the two subunits have fused into a single monomer of double size, through gene duplication. Each half of the structural dimer is a sandwich of 3-4 alpha helices on both sides of an 8-stranded antiparallel beta sheet; the dimer interface is largely composed of the face-to-face meeting of the two beta sheets. The tertiary and quaternary structures of glyoxalase I is similar to those of several other types of proteins. For example, glyoxalase I resembles several proteins that allow bacteria to resist antibiotics such as fosfomycin, bleomycin and mitomycin. Likewise, the unrelated enzymes methylmalonyl-CoA epimerase, 3-demethylubiquinone-9 3-O-methyltransferase and numerous dioxygenases such as biphenyl-2,3-diol 1,2-dioxygenase, catechol 2,3-dioxygenase, 3,4-dihydroxyphenylacetate 2,3-dioxygenase and 4-hydroxyphenylpyruvate dioxygenase all resemble glyoxalase I in structure.

== Research == Alfatradiol administered systemically improved metabolic function, reduced insulin resistance, decreased intra-abdominal fat, and decreased inflammation in old male mice without inducing feminization, suggesting potential usefulness in the treatment of type 2 diabetes.

=== Connective tissue disorders === Marfan's Syndrome is a connective tissue disorder that can lead to chronic aortic or mitral regurgitation. Osteogenesis imperfecta is a disorder in formation of type I collagen and can also lead to chronic aortic regurgitation.

== Clinical significance == FAP expression is seen on activated stromal fibroblasts of more than 90% of all human carcinomas. Stromal fibroblasts play an important role in the development, growth and metastasis of carcinomas. Several approaches to FAP targeting in cancer diagnosis and treatment are currently being tested. In diagnostic imaging radiolabeled FAP inhibitors (FAPIs) are used as PET tracers to visualize tumors. Therapeutic approaches include the use of low molecular weight inhibitors, prodrugs activated by FAP, various anti-FAP antibodies and their conjugates, FAP-CAR T cells, and FAP vaccines. By cleaving FGF-21, FAP is also thought to play a possible role in energy metabolism. Talabostat is an inhibitor of FAP and related enzymes, for which clinical trials have been done, but further research is suspended. Sibrotuzumab is a monoclonal antibody against FAP.

== Mechanism of action == Like other enediynes, kedarcidin chromophore comprises a core structure that forms destructive free radicals, as well as appendages that deliver this "warhead" to its DNA target. Thus, the general mechanism by which kedarcidin chromophore damages DNA is known; however, the details of this process—particularly the necessity of nucleophilic activation—have been disputed.

Sources: en.wikipedia.org

Notes from published material

==== Administration criteria ==== Use of tPA in the United States in treatment of patients who are eligible for its use, have no contraindications, and arrival at the treating facility less than 3 hours after onset of symptoms, is reported to have doubled from 2003 to 2011. Use on patients with mild deficits, of nonwhite race/ethnicity, and oldest old age increased. However, many patients who were eligible for treatment were not treated. tPA has also been given to patients with acute ischemic stroke above age 90 years old. Although a small fraction of patients 90 years and above treated with tPA for acute ischemic stroke recover, most patients have a poor 30-day functional outcome or die. Nonagenarians may do as well as octogenarians following treatment with IV-tPA for acute ischemic stroke. In addition, people with frostbite treated with tPA had fewer amputations than those not treated with tPA.

Devices that integrate (multiple) laboratory functions on a single chip of only millimeters to a few square centimeters in size and that are capable of handling extremely small fluid volumes down to less than picoliters.

von Hagens, Gunther (March 1986). Heidelberg plastination folder: collection of technical leaflets of plastination. Heidelberg: Biodur Products. OCLC 256499636. First published as von Hagens, Gunther (1985). Heidelberger Plastinationshefter Sammlung von Merkblättern zur Plastination (in German). Heidelberg: University of Heidelberg. OCLC 174501422. da Fonseca, Liselotte Hermes; Thomas Kliche (2007). "Verführerische Leichen – verbotener Verfall. "Körperwelten" als gesellschaftliches Schlüsselereignis. Perspektiven Politischer Psychologie". Deutsches Ärzteblatt (in German). 104 (38). von Hagens, Gunther; Klaus Tiedemann; Wilhelm Kriz (March 1987). "The current potential of plastination". Anatomy and Embryology. 175 (4): 411–21. doi:10.1007/BF00309677. PMID 3555158. S2CID 21077765. Whalley, Angelina (2005). Pushing the Limits: Encounters with Body Worlds Creator Gunther von Hagens. Heidelberg: Arts & Sciences. ISBN 978-3-937256-07-8. OCLC 61119531. von Hagens, Gunther (2006). Body Worlds: The Anatomical Exhibition of Real Human Bodies. Heidelberg: Institute für Plastination. ISBN 978-3-937256-04-7. OCLC 69257041. Ottone NE et al. (2015). New contributions to the development of a plastination technique at room temperature with silicone. Anatomical Science International 2015; 90(2):126–35. doi:10.1007/s12565-014-0258-6 Ottone NE et al. (2018). E12 sheet plastination: Techniques and applications. Clinical Anatomy, 31(5):742–756. doi:10.1002/ca.23008 Ottone NE et al. (2020). Extraction of DNA from plastinated tissues. Forensic Science International, 309:110199.

In 1886, Eugen Goldstein discovered canal rays (also known as anode rays) exiting from perforations in the discharge tube. Wilhelm Wien in 1898 showed that these rays had a charge opposite to the negative electrons discovered by J. J. Thomson, but with a much higher mass to charge ratio. Later that year Thomson was able to determine a value for the magnitude of the electric charge, e, and show that the canal rays included material with charge-to-mass ratio (q/m) consistent with the hydrogen ion. Following the discovery of the atomic nucleus by Ernest Rutherford in 1913, Antonius van den Broek proposed that the place of each element in the periodic table (its atomic number) is equal to its nuclear charge. Van den Broek speculated that the nucleus contained alpha particles with four positive charges and two electrons, the first version of the nuclear-electron hypothesis. (The modern model of two positive protons and two neutrons would take many years to discover). Also in 1913 Niels Bohr presented a theory of atomic structure which predicted electronic transitions related to nuclear charge. This was confirmed experimentally by Henry Moseley in 1913 when he showed that the energy of X-ray spectra lines of many elements followed a pattern based on atomic number. In 1919, after a long series of sporadic experiments interrupted by WWI, Rutherford discovered what he called artificial disintegration of nitrogen atoms.

==== Land ==== The Peak Tram, Hong Kong's first public transport system, has provided funicular rail transport between Central and Victoria Peak since 1888. The Central and Western District has an extensive system of escalators and moving pavements, which, together with the Mid-Levels escalator system, is the world's longest outdoor covered escalator system. Hong Kong Tramways' tram network covers a portion of Hong Kong Island, covering from Kennedy Town to Shau Kei Wan, with a branch to Happy Valley. It operates 6 routes and has had a ridership of 42,558 in 2022. It began servicing Hong Kong since 1904. Hong Kong Tramways currently holds the Guinness World Record as the "Largest double-decker tram fleet in service", certified on 30 July 2021, with a fleet of 165 double-decker trams. The fleet of trams was mostly built by Hong Kong Tramways.

Sources: en.wikipedia.org

Background from the literature

is the transmittance of that material. Absorbance is a dimensionless quantity. Nevertheless, the absorbance unit or AU is commonly used in ultraviolet–visible spectroscopy and its high-performance liquid chromatography applications, often in derived units such as the milli-absorbance unit (mAU) or milli-absorbance unit-minutes (mAU×min), a unit of absorbance integrated over time. Absorbance is related to optical depth by

This process is highly efficient in terms of imported materials used up per batch, but is not the most efficient process in energy per kilogram of oxygen. One proposed method of purifying asteroid materials is through the use of carbon monoxide (CO). Heating the material to 500 °F (260 °C) and exposing it to CO causes the metals to form gaseous carbonyls. This vapor can then be distilled to separate out the metal components, and the CO can then be recovered by another heating cycle. Thus an automated ship can scrape up loose surface materials from, say, the relatively nearby 4660 Nereus (in delta-v terms), process the ore using solar heating and CO, and eventually return with a load of almost pure metal. The economics of this process can potentially allow the material to be extracted at one-twentieth the cost of launching from Earth, but it would require a two-year round trip to return any mined ore.

According to an Afghan media outlet, Pakistani aircraft have repeatedly patrolled Afghan airspace over the past two months, promoting Taliban forces to fire at them, which in some cases has resulted in casualties and damage to Afghan civilians. Two TTP militants and a policeman were killed in a clash in Lakki Marwat. On 21 April, Pakistani military claimed to have carried out an operation in Khyber District killing 22 TTP militants while a child was also killed in the crossfire. On 22 April, local Afghan sources reported that Pakistani forces carried out mortar strikes targeting Asadabad, provincial capital of Kunar province. Earlier, local Afghan sources said that the villages of Kochi, Shahbaz and Koremar in Kunar province were targeted by artillery strikes carried out by Pakistani forces. Elsewhere, border areas of Paktika province were also subjected to cross border shelling by Pakistani forces, according to local Afghan sources. No casualties were reported in these attacks, and Taliban officials did not comment on them. On 24 April, TTP attacked a police station in Dera Ismail Khan District using heavy weapons damaging the station and nearby buildings. On 26 April, three civilians were wounded in a Taliban artillery attack at Zalulkhel area in South Waziristan. In response, Pakistan claimed to have destroyed Taliban firing positions and foiled infiltration attempts. On 27 April, seven people were killed and 85 others were injured in Pakistani strikes in Kunar province, including a strike on the Sayed Jamaluddin Afghani University in the provincial capital of Asadabad.

Alli Sebastian Wolf created a golden 100∶1 scale model of the clitoris in 2017, called the Glitoris and said, she hopes knowledge of the clitoris will soon become so uncontroversial that making art about them would be as irrelevant as making art about penises. Other projects listed by the BBC include Clito Clito, body-positive jewellery made in Berlin; Clitorissima, a documentary intended to normalize mother-daughter conversations about the clitoris; and a ClitArt festival in London, encompassing spoken word performances as well as visual art. French art collective Les Infemmes (a blend word of "infamous" and "women") published a fanzine whose title can be translated as "The Clit Cheatsheet".

Plasma is normally yellow due to bilirubin, carotenoids, hemoglobin, and transferrin. In abnormal cases, plasma can have varying shades of orange, green, or brown. The green color can be due to ceruloplasmin or sulfhemoglobin. The latter may form due to medicines that are able to form sulfonamides once ingested. A dark brown or reddish color can appear due to hemolysis, in which methemoglobin is released from broken blood cells. Plasma is normally relatively transparent, but sometimes it can be opaque. Opaqueness is typically due to elevated content of lipids like cholesterol and triglycerides.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Is SR9009 a steroid?

No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.

Has SR9009 been tested in humans?

Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.

What is SR9009?

It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.

Network